Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the rate and extent of absorption Ranbaxy
Laboratories Limited, India, amoxicillin - clavulanic acid and GlaxoSmithKline, U.S.A.
(Augmentin ES-600), amoxicillin - clavulanic acid, administered as a 1 x 5 mL (600 mg - 42.9
mg) oral suspension, under fasting conditions.